An interventional study of Mindfulness-Based Relapse Prevention in Benzodiazepine Dependence, sponsored by Federal University of São Paulo. Completed at 1 site in Brazil. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-09.
Sponsored by Federal University of São Paulo · Not applicable, Interventional, and Supportive care
Benzodiazepines (BZD) are the most prescribed psychiatric drugs in Brazil, especially for women. Although it is recommended that the use of BZD is not greater than four weeks, there are many cases of prolonged use due to the lack of treatment options for dealing with complaints of insomnia. Given this, the aim of this project is to evaluate the program Mindfulness-Based Relapse Prevention (MBRP) for adult women with chronic use of benzodiazepine (BZD) to induce sleep. Specifically aims to evaluate if the MBRP program, can reduce the pattern of use and level of dependence of chronic users of BZD under gradual reduction (tapering) or cessation of the use of BZD. This study will be conducted at the Drug Dependency Unit (UDED) of the Department of Psychobiology of Federal University of São Paulo. The study will count with two groups: intervention group (IG) and control group (CG) (that will stay in the waitlist until the eighth month . The sample will comprise 100 women with chronic use of BZD as hypnotics, 50 will be randomized in the IG condition and 50 in the CG condition. Changes will be evaluated on several variables such as cessation and dependence of BZD, quality of life, sleep, anxiety, depression and sexual satisfaction before and after the intervention in both groups. The data will be submitted to descriptive and inferential bivariate and multivariate statistic analyzes. It is hoped that this study create subsidies for the development of complementary interventions for the management of withdrawal symptoms in chronic users of BZD.
4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.
This study's enrollment of 76 is above the median of 50 across 3,374 interventional studies indexed under Recurrence.
Browse Recurrence studies →Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Mindfulness-Based Relapse Prevention
Behavioral: Mindfulness-Based Relapse Prevention
this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
reduction of benzodiazepine use
We will evaluate the reduction through a percentual comparison between the dose the patient is using at follow-up assessments and the dose related at the beginning of the study.
Time frame: Change from baseline in benzodiazepine use at 8 months.
Severity of insomnia
We will evluate the severity os insomnia with the Insomnia Severity Index (ISI) which is a self-report questionnaire and consists of seven items that evaluate severity of sleep onset, sleep maintenance and early morning awakening problems; sleep dissatisfaction; interference of sleep difficulties with daytime functioning; noticeability of sleep problems by others, and distress caused by sleep difficulties. The score for each item ranges from 0 to 4, totaling 0 to 28 points, with a higher score indicating greater insomnia severity.
Time frame: Change from baseline in insomnia severity at 8 months
Stage of change related to benzodiazepine use
This will be measured by an analogic rule from 1 to 10, in which 1 means "not ready to change" and 10 means "actively working in the change"
Time frame: Change from Baseline of the stage of change at 8 months
self report mindfulness level
This will be measured with the self report questionnaires: Five Facet Mindfulness Questionnaire. This is a self-report questionnaire and do not have a specific metric to measure mindfulness. The scores are absolute and a higher score denotes higher levels of mindfulness
Time frame: Change in mindfulness level from baseline at 8 months
Level of Benzodiazepine dependence (from mild to severe)
this will be measured through the Benzodiazepine Dependence Self-Report Questionnaire, which is a self report questionnaire and do not provides a specific metric to measure the severity of dependence.
Time frame: change in benzodiazepine dependence severity from baseline at 8 months
Symptoms of depression
The symptoms of depression will be measured through the Center for Epidemiologic Studies Depression Scale - CES-D. As it is a self report scale, there is no specific metric to measure depression.
Time frame: Change in symptoms of depression from baseline at 8 months
Sleep Quality
will be measured through the Pittsburgh Sleep Quality Index
Time frame: Change in sleep quality from baseline at 8 months
menopausal symptoms (Kupperman index)
Time frame: change in menopausal symptoms from baseline at 8 months
Female Sexual Satisfaction
Time frame: change in female sexual satisfaction from baseline at 8 months
presence of benzodiazepines metabolites identified with a toxicology urinalysis
Time frame: Change in benzodiazepine metabolites from baseline at eight months
Epigenetic modifications
Blood collection will be held, and the plasma will be analyzed to evaluate levels of homocysteine and cysteine , two aminoacids that are related to epigenetic modifications that can modulate the behavioral responses resulting from the practice of meditation
Time frame: Baseline and 2 month follow-up
Trait Anxiety
Evaluated using the State and Trait Anxiety Index (STAI), validated in Brazil (α = 0.87). We used only the subscale of trait anxiety, less susceptible to environmental alterations. This subscale is composed by 20 items on a four-point Likert scale ("almost never", "sometimes", "often", "almost always"), in which the participant is instructed to answer "how do you usually feel". The Cronbach α in this sample was 0.90.
Time frame: Baseline, 2, 4 6 and 8 months follow-ups
Plan to share: Undecided
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of São Paulo